Free delivery over $100 Learn more

30 days return period Learn more
SKU: 0274ATC

Panc 10.05 Human Pancreas Adenocarcinoma Epithelial Cells

Tumor Cell Lines > Pancreatic Cancer Cell Lines

Product Type: Human Pancreas Cancer Cell Lines

Species: Human

Cell Type: Epithelial Cells

Source Organ: Pancreas

$1,249.00
Size

Care information

Display general product information or specific product information using metafields.

Delivery and Shipping

Add some general information about your delivery and shipping policies.

Cell Name: Panc 10.05

Panc 10.05 Is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.

  • Description
    Panc 10.05 is a human pancreatic ductal adenocarcinoma (PDAC) cell line established in 1992 from a primary pancreatic adenocarcinoma of an 81-year-old male patient. This cell line exhibits an epithelial-like morphology with adherent growth properties and a doubling time of approximately 20~30 hours (1). Panc 10.05 carries the KRAS G12D mutation – an oncogenic driver frequently observed in PDAC. As well, they express epithelial markers including cytokeratin 7/18. The cell line is tumorigenic in immunocompromised mice, making it suitable for in vivo studies of pancreatic cancer progression.
  • Product Name
    Panc 10.05
  • Product Type
    Human Pancreas Cancer Cell Lines
  • Species
    Human
  • Cell Type
    Epithelial
  • Source Organ
    Pancreas
  • Disease
    Adenocarcinoma
  • Product Type
    Human Pancreas Cancer Cell Lines
  • Growth Conditions
    37 °C, 5% CO2
  • Application
    Panc 10.05 cell line serves as a valuable tool for pancreatic cancer research, particularly for evaluating therapeutic strategies targeting KRAS-driven oncogenesis. Its genetic profile and tumorigenic behavior make it an effective model for assessing cell proliferation, apoptosis and tumor growth inhibition in response to experimental treatments. Furthermore, Panc 10.05 is suitable for xenograft studies, where its moderate tumorigenicity supports the preclinical evaluation of potential anti-angiogenic agents, cytotoxic compounds and targeted therapies. This cell line contributes to the advancement of precision medicine approaches in pancreatic ductal adenocarcinoma.
  • Size/Quantity
    1 vial
  • Recommended Medium And Supplement

    RPMI 1640 + 10% FBS
  • Shipping Conditions
    Dry Ice
  • Storage
    Liquid Nitrogen
  • Biosafety Level
    1

Payment & Security

Payment methods

    Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

    • Visit our support center

      Expert help & advice

    • Check your order status

      Updates & tracking

    • Returns & exchanges

      All you need to know

    • Price-match guarantee

      Our promise to you